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determine whether these short-term improvements will re-
sult in improved long-term outcomes. We continue to use
home surveillance to discriminate patients at risk for inter-
stage death.
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Discussion
Dr J. William Gaynor (Philadelphia, Pa). I congratulate Gha-
nayem and coauthors on this excellent report addressing the im-
portant and troubling issue of interstage mortality after successful
S1P. This is yet another important contribution to the management
of these difficult cases from your institution.
In this study, detection of home-monitored events, either de-
creased oxygen saturation or poor weight gain, led to earlier
evaluation of these patients and frequently earlier performance of
the superior cavopulmonary connection. There was no interstage
mortality in the relatively small group of infants for whom home
monitoring was used.
Dr Ghanayem, I have several questions. First, we recently
reviewed risk factors for death after S1P in 158 infants during a
3.5-year period. In 46% of these infants there were additional risk
factors, such as low birth weight (2.5 kg); presence of additional
cardiac defects at the time of S1P, such as interrupted aortic arch,
moderate to severe tricuspid regurgitation, and anomalies of pul-
monary or venous drainage; or presence of major extracardiac
anomalies or genetic syndromes.
The interstage mortality in that series was approximately 10%,
similar to your group A. In a multivariable analysis, the strongest
predictors of interstage mortality were the presence of additional
cardiac defects and the presence of an extracardiac anomaly or
genetic syndrome. In your series, how many infants had either
additional cardiac defects or extracardiac anomalies? And what
was the impact of these associated anomalies on interstage mor-
tality?
Second, it would appear that in group A several of the deaths
occurred at a relatively early age, 50 to 70 days. These deaths
appeared to occur before the age at which home monitoring events
were detected in group B and before the age at which most group
B patients underwent cavopulmonary connection. Do you attribute
the lack of these early deaths and this decreased very early mor-
tality to the home monitoring program, or does this simply repre-
sent increasing institutional experience with the management of
these infants or some other change in management?
Third, an intriguing finding of your study is the decrease in
growth velocity at approximately 5 months of age. This implies
that there may be no advantage to delaying cavopulmonary con-
nection even for children who are doing relatively well. What is
your current policy for timing of cavopulmonary connection for
children who have no home monitoring events and are otherwise
doing well?
Fourth, the presence of aortic atresia, particularly with a dimin-
utive ascending aorta, is a potential risk factor for coronary isch-
emia and interstage mortality. What was the incidence of very
small ascending aorta, less than 2 mm, in your series? Was there
any difference between group A and group B?
Finally, I was intrigued by the fact that many of your patients
with recurrent arch obstruction undergo surgical intervention
rather than balloon dilatation of the arch. What are your reasons for
choosing surgical reconstruction rather than balloon dilatation?
I again congratulate you on your excellent study.
Dr Ghanayem. Thank you, Dr Gaynor, for your remarks. The
presence of additional cardiac defects, such as preoperative mod-
erate to severe tricuspid regurgitation, anomalous origin of the
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subclavian artery, or anomalies of pulmonary venous drainage,
occurred in approximately 12% of the entire cohort, with no
difference between the unmonitored and home-monitored groups.
Among the interstage deaths in the earlier group, there was 1
patient with Turner syndrome; however, the incidence of extracar-
diac defects was not different between groups.
I do agree that an institutional learning curve has affected
survival. Part of that learning curve is the appreciation that there
are patients at risk for interstage death whom we have not been
able to previously identify. In the unmonitored group, 4 of 9
interstage deaths occurred between 50 and 70 days, with the other
5 deaths occurring between 90 and 120 days. Although there was
an absence of early deaths within the home-monitored group, there
were several patients seen as a result of home-detected events for
medical or surgical intervention between the ages of 50 and 70
days, with the earliest presentation prompting intervention occur-
ring at 41 days. Also of significance was that the mean age for S2P
was 111 days in patients with home-detected events versus 156
days in patients without home-detected events. What I believe we
have learned, and successfully applied, is that there are changes in
the health of these patients occurring during a short period of
several days that would be missed by even frequent outpatient
clinic evaluations and that recognition of desaturation, poor weight
gain, and acute weight loss may better discriminate those patients
at risk for interstage death, thus allowing earlier intervention.
The third question, regarding the timing of cavopulmonary
connection, is one that we have contemplated as well. Because
growth velocity appears to plateau at 4 to 5 months of age, why not
advocate early S2P for everyone? It is clear from our experiences
and those of others that although cavopulmonary connection can
be successfully accomplished in patients as young as 6 weeks, the
postoperative course these patients is prolonged relative to older
patients. We must assume that the very young patient is at in-
creased risk for mortality and morbidity after cavopulmonary
connection, and this therapy thus should be reserved for those in
whom the risk-benefit ratio is favorable (those who are struggling
during the interstage period). Our current approach for timing of
S2P depends on both growth and the degree of cyanosis. If growth
velocity appears to plateau or the patient shows progressive hy-
poxemia with saturations consistently less than 70%, we will
proceed with S2P. Alternatively, if growth is good and saturations
remain acceptable, we will delay S2P until 5 to 6 months of age.
Although the presence of aortic atresia has previously been
identified as a risk factor for coronary ischemia and interstage
death, in our study it was not a risk factor for interstage death.
The incidence of very small ascending aortas, less than or equal
to 2 mm, was not different between groups: 40% for the group
without home surveillance and 55% for the home-monitored
group.
The incidence of recurrent arch obstruction was similar be-
tween groups. Only 3 patients in group A and 1 patient in group B
had diagnoses made as a result of symptoms that were attributable
to recurrent arch obstruction. Most of the patients with interven-
tions for arch obstruction were symptom free, and the diagnosis
was made during routine pre-S2P evaluation. When that has oc-
curred, our approach has been to proceed with S2P and surgical
arch revision, rather than performing balloon dilatation and delay-
ing S2P until there is sufficient recovery from the interventional
catheterization.
Dr Charles D. Fraser (Houston, Tex). I think that all of us who
deal with patients with HLHS are forever frustrated by the inter-
stage losses, and I think you are to be congratulated in tackling this
problem. I wanted to ask you some practical questions about how
you manage this program.
First, who pays for the monitors? Who pays for the pulse
oximeters and the scales for the patients at home?
How do you handle non–English-speaking patients, of which
many of us have a significant population?
Who collects the data and communicates with the families? I
can imagine that having patients with HLHS at home with con-
tinuous pulse oximetry must generate a lot of telephone calls, so
who handles all that?
Dr Ghanayem. Generally, health insurance companies have
been willing to provide pulse oximeters and scales for these
cyanotic infants at risk for poor growth. This has been facilitated
by early correspondence to insurers, explaining the interstage risks
and the importance of monitoring physiologic variances that are
well-accepted indicators of infant health.
Some of the public aid patients have been more challenging in
providing quality scales accurate to 10 g. We now have scales
donated to our hospital, and these we loan to the families until the
time of S2P.
Thus far we have had only one non–English-speaking family
home with monitoring, and through a translator we were quite
successful in training the family to monitor their child. In fact, this
family successfully came to our attention during an acute illness as
a result of home-detected desaturations.
Collection of the data has not been difficult, and parents have
been keen about this project. We have developed fill-in-the-blank
data sheets and have been pleasantly surprised and rewarded by the
thoroughness with which the parents keep records. Parents are
instructed to contact one of three nurses working in the cardi-
ology clinic with concerns or if any aforementioned criteria are
met.
Dr Thomas L. Spray (Philadelphia, Pa). This is an important
area, but one concern that I have is that basically there weren’t any
deaths in the second group. Therefore, how can you really say that
your intervention changed the natural history of these patients? In
the early group, concurrent illness and tricuspid regurgitation were
the causes of death in most cases. But it’s not clear that those
patients had events that would have been picked up by monitoring
and could have been treated in a fashion that would have changed
their outcome. I know you intervened early when you found
problems, but does that really tell you that these patients would
have gone on to interstage death?
Dr Ghanayem. Dr Spray, you correctly point out that patients
were not randomly assigned to intervention versus no intervention
if home-monitored events were detected. Therefore we cannot
definitively say that the patients that breached home monitoring
criteria benefited from intervention. However, the criteria used
would likely prompt further investigation if spotted at a routine
clinic visit, and we therefore suggest that home monitoring al-
lowed early identification of well-accepted criteria for interven-
tion. The patient with diminished arterial saturation, poor weight
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gain, or acute weight loss would be at greatly increased risk for
death because of the limited physiologic reserve of this patient
population.
Dr Frank A. Pigula (Pittsburgh, Pa). I congratulate you on a
nice presentation. My question involves whether any anticoagula-
tion regimen is used for these patients, either in the form of aspirin
or low–molecular weight heparin. What you think the role of that
may be in the interim management of these patients?
Dr Ghanayem. Dr Pigula, all patients receive aspirin unless
they are more cyanotic than expected or we are concerned about
shunt flow, in which case we will use subcutaneous low–molecular
weight heparin injections for interstage anticoagulation.
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